14 results about "Pigmented retinal epithelium" patented technology

The application relates to the technical field of ophthalmic surgical instruments, in particular to an ophthalmic internal limiting membrane tampon, which can protectively and automatically rebound when the tampon is operated with excessive force during a'mechanical' tampon process, so as to prevent iatrogenic retinal pigment epithelial layer damage at the bottom of a macular hole. The device comprises a sleeve-shaped handle, a spring and a probe are arranged in the handle along the length direction of the handle; the probe comprises a probe main body and a probe base, and the two ends of the probe base are connected with the spring and the probe main body respectively; an outer thread is arranged on the outer side of the probe base, and a tensioning wheel is arranged on the handle; the outer thread is divided into at least three thread regions arranged along the length direction of the probe base, including a first thread region, a second thread region and a third thread region; the threads in the first thread region, the second thread region and the third thread region correspond to first threads, second threads and third threads respectively; and the diameters of the second threads are all larger than the diameters of the first threads and the third threads.

Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.

This invention relates to a self-assembling polypeptide for regulating the permeability of retinal pigment epithelium (RPE), its preparation method, and its applications. The self-assembling polypeptide comprises an integrin receptor-targeting peptide, a self-assembling polypeptide, and a hydrophobic molecule sequentially linked. The self-assembling polypeptide designed in this invention can self-assemble into nanoparticles and specifically target RPE cells. After interacting with receptors on the cell membrane, the nanoparticles transform into nanofibers, achieving rapid targeted enrichment of RPE tissue. Furthermore, by regulating the permeability of RPE tissue, it can enhance the transcellular drug transport capacity, providing a new clinical application strategy for the treatment of macular neovascularization, especially polypoid choroidal vascular lesions.

Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.

A method of detecting one or mor change in an eye and method diagnosing or proving an indication of an eye disease or eye condition or a neurogenerative disease or condition, or a predisposition thereto are disclosed. The method of detection comprises comparing an image of the eye with at least one asynchronous image of the eye to thereby detect the one or more change in the eye wherein the change comprises a darkening or lightening in pigment of the Retinal Pigment Epithelium (RPE) in the macula. The method of diagnosing or providing an indication of an eye disease or eye condition or a neurodegenerative disease or condition or a predisposition thereto comprises the same comparison and when the change is detected, providing a diagnosis of indication of or predisposition to an eye disease or eye condition or a neurodegenerative disease or condition or a predisposition thereto.

FIELD: ophthalmology.SUBSTANCE: used for objective differential diagnostics of the anatomical form of the optic nerve disc (OND) deepening. Optical coherence tomography is performed on the Optovue RTVue XR Avanti System using the 3D Disc program. Images of the optic disc are obtained in the horizontal plane, a straight line is drawn between the visible boundaries of the retinal pigment epithelium (RPE) and the position and shape of the bottom of the OND deepening are assessed. When the depression is at the level of the RPE and the angle of its bottom is less than or equal to 90° a triangular shape is defined. If the depression is located above the RPE level and the angle of its bottom is more than 90° a flat shape is defined. If the depression is below the RPE level and the bottom angle is less than or equal to 90° a wedge shape is defined. If the depression is below the RPE level, and its bottom forms a base and two angles, a trapezoidal shape is defined.EFFECT: improving the accuracy, objectivity and reproducibility of determining the individual anatomical shape of the OND excavation by using a stable anatomical landmark – the RPE and standardized geometric parameters, which eliminates subjective error in diagnosis.1 cl, 7 dwg, 1 tbl, 3 ex

A method of treating and / or preventing disease involving retinal pigment epithelium, including administering compound of formula (I)or a pharmaceutically acceptable salt, a racemic mixture, a corresponding enantiomer or a corresponding diastereomer thereof, wherein: R1, R11 and R12 are independently selected from the group consisting of hydrogen, fluoro, chloro, methoxy, trifluoromethyl, methyl and difluoromethoxy, whereby at least one of R1, R11 and R12 is not hydrogen, B is selected from the group consisting of a residue of formula (II), (III), (IV), (V), (VI) and (VII)wherein, “*” denotes point of attachment to remainder of the molecule, and R2, R3, R4, R5, R2I, R3I, R4I, R5I, R2II, R3II, R4II, R5II, R2III, R3III, R4III, R5III, R2IV, R3IV, R4IV, R5IV, R2V, R3V, R4V, R5V are independently selected from the group consisting of hydrogen, a linear or branched alkyl having 1 to 3 carbon atoms, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, trifluoromethyl and difluoromethoxy.

The present invention relates to a method for treating and / or preventing diseases involving the retinal pigment epithelium, which comprises administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, a racemic mixture, a corresponding enantiomer, or, where appropriate, a corresponding diastereomer: [Formula 1] TIFF2023549640000109.tif27151[In the formula, X is either NH or O; R 11 , R 12 and R 13 are independently selected from the group consisting of a hydrogen atom, a fluorine atom, a chlorine atom, a trifluoromethyl group, a methyl group, and a difluoromethoxy group; A is selected from the group consisting of residues of formula (II), (III), (IV), (V), (VI), (VII) or (VIII): [Case 2] TIFF2023549640000110.tif76151 (in the formula, "*" indicates the point of attachment to the rest of the molecule; R2, R3, R4, R5, R2 I , R3 I , R4 I , R5 I , R2 II , R3 II , R4 II , R5 II , R2 III , R3 III , R4 III , R5 III , R2 IV , R3 IV , R4 IV , R5 IV , R2 V , R3 V , R4 V , R5 V , R2 VI , R3 VI , R4 VI and R5 VIare independently selected from the group consisting of a hydrogen atom, a linear or branched alkyl group having 1 to 3 carbon atoms, a fluorine atom, a chlorine atom, a bromine atom, a methoxy group, an ethoxy group, a propoxy group, a trifluoromethyl group, a 2,2,2-trifluoroethyl group, and a difluoromethoxy group; In the residue of formula (VI), R6 is selected from the group consisting of a hydrogen atom, a linear or branched alkyl group having 1 to 3 carbon atoms, a trifluoromethyl group, and a 2,2,2-trifluoroethyl group.

Systems and methods described herein provide improved techniques for displaying imaging markers to verify biometric measurements. One method includes: receiving an indication to initiate a first optical coherence tomography (OCT) scan of an eye; initiating the first OCT scan of the eye based on the received indication; generating a first OCT image of the eye based on the first OCT scan; detecting a retinal pigment epithelium (RPE) and a fovea in the eye based on the first OCT image; displaying, to a user, a first augmented OCT image based on such detection, the first augmented OCT image displaying: a first virtual marker that segments at least a portion of the detected RPE; and a second virtual marker, wherein the second virtual marker visually identifies a location of the detected fovea, and wherein the second virtual marker is a radial line through the location of the detected fovea.

The invention provides a method for producing a retinal tissue by (1) subjecting pluripotent stem cells to floating culture in a serum-free medium containing a substance inhibiting the Wnt signal pathway to form an aggregate of pluripotent stem cells, (2) subjecting the aggregate to floating culture in a serum-free medium containing a basement membrane preparation, and then (3) subjecting the aggregate to floating culture in a serumcontaining medium. The invention also provides a method for producing an optic-cup-like structure, a method for producing a retinal pigment epithelium, and a method for producing a retinal layer-specific neural cell.

The present invention relates to a pharmaceutical composition for use in the treatment of a disease involving undesired migration, proliferation and / or metaplasia of retinal pigment epithelium (RPE) cells in a subject wherein the pharmaceutical composition comprises at least one epidermal growth factor receptor (EGFR) antagonist.

The application provides use of an ELN gene or a plasmid or virus containing the same in preparation of a medicament for repairing aging choroid and / or retinal pigment epithelium. The application constructs an ELN overexpression vector, overexpresses the gene in a mouse eyeball, increases actin in a choroid layer and an RPE layer, and is beneficial to maintaining the structural morphology of the choroid and the RPE layer; and can maintain the tightness of a basal surface of the RPE layer and the integrity of the RPE structure, maintain the smoothness of a fiber structure of the choroid layer, and has no obvious influence on blood vessels and pigments of the choroid layer. It is illustrated that the ELN gene can be used for improving relaxation of the choroid and the RPE structure, remodeling the aging choroid and the RPE, and has application prospects in preparation of a medicament for repairing aging choroid and / or retinal pigment epithelium, such as a medicament for preventing and treating age-related macular degeneration.

Central Serous chorioretinopathy (CSCR) is primarily an ocular disease, affecting the choroid and the retinal pigment epithelium. To date, no systemic biomarker of CSCR have been discovered that could link both forms and help the diagnosis in challenging cases. In the present invention, the inventors measure in European cohorts of CSCR patients (n=168) with (n=90) or without epitheliopathy (n=78) and a cohort of 153 control subjects without any ocular disease history, the serum levels of NGAL and the NGAL / MMP9 complex. Serum NGAL (ng / ml) was significantly higher in the control group (108.8±46.8) than in the CSCR cohort (80.4±46.4, p<0.0001). Serum NGAL (ng / ml) was significantly lower in the acute / recurrent cohort (n=78, 71.3±32.1) than in the control and, than in the chronic cohort (n=90, 88.3±55, p=0.03). Similarly, Serum NGAL / MMP9 (ng / ml) levels was lower in the whole CSCR cohort (44.5±39.6) as compared to the controls (77.6±47.8, p<0.0001). Serum NGAL / MMP9 (ng / ml) were significantly lower in the acute / recurrent cohort (37.6±37.9) than in the control and, than in the chronic cohort (50.5±40.3, p=0.002). Thus, in both forms of CSCR serum NGAL and NGAL / MMP9 are lower than in the control population, providing a biological link between the two forms and a potential susceptibility to oxidative stress and innate immune dysregulation. Systemic LCN2 being elevated in other retinal diseases, it represents a specific biomarker for CSCR.